CHICAGO, Nov. 30 /PRNewswire/ -- Breast-Specific Gamma Imaging (BSGI) significantly contributes to the detection of malignant or high-risk lesions in patients with negative or indeterminate mammographic findings, according to results of a multicenter study presented today at the annual meeting of the Radiological Society of North America (RSNA).
In this retrospective study, BSGI was utilized in a total of 2,004 patients. Pathology or follow-up imaging was available for 1,042 cases resulting in 250 positive and 792 negative findings. BSGI demonstrated an overall sensitivity of 91 percent and specificity of 77 percent.
BSGI for the study was conducted using a Dilon 6800 Gamma Camera, a high-resolution, small field-of-view gamma camera, optimized to perform BSGI. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than the normal surrounding tissue and generally appear as “hot spots” on the BSGI image.
About Dilon Diagnostics
Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative medical imaging products to market. Dilon’s cornerstone product, the Dilon 6800, is a high-resolution, compact gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Diagnostics please visit www.dilon.com.
CONTACT: Lori Ferguson of Dilon Diagnostics, C: +1-757-303-6000, O:
+1-757-269-4910 x 316, lferguson@dilon.com
Web site: http://www.dilon.com/
